Ettore D’Argento

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maïo, Olga Nigro et al. · Journal for ImmunoTherapy of Cancer · 2021 · 144 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases

Carlo Barone, Alessandra Cassano, Michele Basso et al. · British Journal of Cancer · 2007 · 127 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna et al. · Cancer Immunology Immunotherapy · 2020 · 93 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna et al. · Clinical Lung Cancer · 2020 · 84 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

Giuseppe Luigi Banna, Alessio Cortellini, Diego Cortinovis et al. · ESMO Open · 2021 · 62 citations · Full text

Medicine, Immunology, Oncology +17